πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10426786

Mitigation of epileptic seizures by combination therapy using benzodiazepines and neuroste

The Regents of the University of California Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10420799

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10421963

Oligonucleotide therapy for leber congenital amaurosis

ProQR Therapeutics II B.V. Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10406177

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10406169

Methods of monitoring estriol therapy

The Regents of the University of California Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10407488

Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulat

The Regents of the University of California Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10398734

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392439

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385395

Diagnostic tools for response to 6-thiopurine therapy

The Regents of the University of California Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10369141

Methods of improving cell-based therapy

The Regents of the University of California Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10369173

Optimized methods for generation of cardiac stem cells from cardiac tissue and their use i

Capricor, Inc. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10369158

Pharmaceutical packaging for estriol therapy

The Regents of the University of California Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10363273

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10357553

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10342815

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10335382

Use of hydrogen sulfide synthesis inhibitors for cancer therapy

The Board of Regents of the University of Texas System Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10322095

Endoxifen for local transdermal therapy to the breast

Northwestern University Β· Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10322146

Methods of conditioning patients for T cell therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10316050

PT (IV) complexes containing 4,4β€²-disubstituted-2,2β€²-bipyridyl and their use in cancer the

THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10314924

RPGR gene therapy for retinitis pigmentosa

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10300074

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10301365

Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

The Regents of the University of California Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10293056

Methods and compositions for non-viral gene therapy for treatment of hyperproliferative di

The Board of Regents of the University of Texas System Β· Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10272113

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted